关于晚期慢性髓性白血病管理的最新情况
Nicholas J Short1, Jayastu Senapati2, Elias Jabbour2
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. nshort@mdanderson.org.
晚期慢性髓性白血病 (CML) 需要专门治疗. 后一代氨酸激酶抑制剂和组合疗法显示出有望改善攻击性CML亚型的结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 大多数慢性髓性白血病 (CML) 患者存在慢性阶段,预期寿命正常.
- 一组CML患者出现或进展到加速阶段 (AP) 或爆发阶段 (BP),表明疾病已晚.
- 晚期CML代表了更具侵略性的疾病形式,预后较差.
研究的目的:
- 讨论晚期CML的诊断考虑因素.
- 对加速和爆发阶段CML的当代管理策略进行审查.
- 要突出治疗晚期CML的最新进展.
主要方法:
- 审查关于晚期CML诊断和治疗的当前文献.
- 分析与不同治疗方法相关的结果.
- 讨论新兴的治疗方式和临床试验.
主要成果:
- 后一代BCR::ABL1氨酸激酶抑制剂 (TKI),如波纳替尼,可能在晚期CML中提供更好的结果.
- 对于爆发期CML (CML-BP),针对爆发性免疫表型的组合疗法显示出比TKI单一疗法更好的结果.
- 同源干细胞移植在CML-AP中存在争议,但在CML-BP中改善了结果.
结论:
- 晚期CML,特别是CML-BP,仍然是一个高风险的亚型.
- 使用后一代TKI的新组合策略正在调查中,可能会改善患者的治疗结果.
- 当代管理侧重于强效的TKI和组合疗法,干细胞移植在CML-BP中发挥作用.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chronic Kidney Disease IV: Nursing Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Differentiation of Common Myeloid Progenitor Cells
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
